Condition: Digestive System Neoplasms · Sponsor: Sir Run Run Shaw Hospital
The purpose of this study is to assess the safety, feasibility, and efficacy of personalized mRNA vaccine iNeo-Vac-R01 alone in subjects with advanced digestive system neoplasms.
This description comes directly from the study's public registry record.
Xiujun Cai, MD · 0086-0571-86006605 · caixiujunzju@yahoo.com.cn
Always discuss trial participation with your own doctor first.
| Department of General Surgery, Institute of Minimally Invasive Surgery, Sir Run Run Shaw Hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06019702